Raymond James Reaffirms Their Buy Rating on Biosyent (RX)


Biosyent (RX), the Healthcare company, was revisited by a Wall Street analyst today. The company received a Buy rating from Raymond James’ analyst David Novak, with a C$11 price target.

According to TipRanks.com, Novak is ranked #4474 out of 5129 analysts.

Read also: AcelRx (ACRX) Tumbles After Stock Offering Prices at Deep Discount

Currently, the analyst consensus on Biosyent is a Moderate Buy with an average price target of C$11.

Biosyent’s market cap is currently C$104.5M and has a P/E ratio of 18.9. The company has a Price to Book ratio of 4.15.

BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System, and Cysview. The company was founded on April 28, 1947 and is headquartered in Ontario, Canada.

The company’s shares closed on Thursday at C$7.15, close to its 52-week low of C$6.93.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts